Open AccessSIRT4 Overexpression Promotes the Inhibition of Cell Proliferation and Invasion in Prostate Cancer
Author(s) -
Abdul-Nazif Mahmud,
Feilun Cui,
Bin Xue,
Jianpeng Hu,
Tingjun Liu,
Muslimat Kehinde Adebis,
Said Abdulrahman Salim Mzee,
Aaron Gia Kanton
Publication year - 2020
Publication title -
international journal of scientific research in science and technology
Language(s) - English
Resource type - Journals
eISSN - 2395-602X
pISSN - 2395-6011
DOI - 10.32628/ijsrst207347
Subject(s) - lncap , cell growth , prostate cancer , cancer research , sirtuin , biology , cell , sirtuin 1 , cancer cell , cancer , chemistry , microbiology and biotechnology , downregulation and upregulation , nad+ kinase , biochemistry , enzyme , genetics , gene
Background: SIRT4 is among the few characterized individual sirtuin groups of nicotinamide adenine dinucleotide-dependent enzymes base in the mitochondria that facilitate several significant processes at the cellular level including stress response, metabolism and longevity. SIRT4 can suppress and inhibits the growth, proliferation and transformation of tumor cells such as colorectal and gastric tumors by suppressing glutamine anaplerosis, but there is no research that reveal the role and function SIRT4 plays in the development of prostate tumor. Methods: Overexpression of SIRT4 in prostate cancer cell lines LNCaP was determined using RT-qPCR and Western blotting analyses. CCK-8 and transwell analysis were utilized to establish SIRT4 overexpression effects on cell proliferation and cell invasion respectively. Results: This study first established SIRT4 overexpression in prostate cancer cell lines LNCaP, functional experiment such as CCK-8 assay reveals that, overexpression of SIRT4 suppressed cell proliferation. In addition, transwell assay reveals that, SIRT4 overexpression inhibits cell invasion. Conclusions: This research findings reveals that, SIRT4 function to suppress prostate cancer cells by impeding the proliferation and invasion of LNCaP cells. SIRT4 may serve as a new treatment target for prostate tumor.